MTOR and neoplasm: This includes synergistic anti-tumor activities of MEK therapeutics when paired with inhibitors of CDK4/6 [41]; SHP2 [42]; the mammalian target of rapamycin (mTOR) [40]; and several different receptor tyrosine kinases (RTKs), including tyrosine kinase 2 (TYK2) [45], platelet-derived growth factor receptor (PDGFR) [46], and mesenchymal epithelial transition receptor (MET) [43].